PapersFlow Research Brief
Hormonal and reproductive studies
Research Guide
What is Hormonal and reproductive studies?
Hormonal and reproductive studies is a field in endocrinology that examines the long-term effects of testosterone levels and therapy on men's health, including aging, metabolic syndrome, cardiovascular risk, muscle strength, diabetes, androgen deficiency, and anabolic steroid use.
This field encompasses 88,650 published works focused on testosterone's role in men's health. Studies demonstrate age-related declines in total and free testosterone levels in healthy men, as shown by Harman et al. (2001) in 'Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men'. Key research also addresses estimation methods for free testosterone in serum, per Vermeulen et al. (1999) in 'A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum'.
Topic Hierarchy
Research Sub-Topics
Testosterone Replacement Therapy in Aging Men
This sub-topic evaluates long-term safety and efficacy of testosterone therapy for hypogonadism in elderly men, focusing on symptomatic improvements and monitoring protocols. Researchers conduct RCTs on vitality and frailty.
Testosterone and Metabolic Syndrome
Studies the bidirectional links between low testosterone and metabolic syndrome components like insulin resistance, obesity, and dyslipidemia. Includes intervention trials on body composition.
Testosterone and Cardiovascular Risk
This examines associations between endogenous testosterone levels, therapy, and CVD events like MI and stroke in cohort studies. Researchers address prostate safety and lipid effects.
Androgen Deficiency in Type 2 Diabetes
Focuses on prevalence, mechanisms, and testosterone treatment outcomes in diabetic men, including glycemic control and erectile function. Meta-analyses synthesize trial data.
Anabolic Steroid Effects on Muscle Strength
Investigates supraphysiological androgens' impacts on muscle hypertrophy, strength gains, and recovery in athletes and sarcopenia patients. Studies include doping detection and long-term risks.
Why It Matters
Hormonal and reproductive studies inform treatments for conditions linked to testosterone deficiency, such as erectile dysfunction assessed via the International Index of Erectile Function (IIEF), developed by Rosen et al. (1997) in 'The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction', which has been cited 5719 times. In prostate cancer, abiraterone extends radiographic progression-free survival in metastatic cases without prior chemotherapy, as reported by Ryan et al. (2012) in 'Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy', delaying chemotherapy initiation. Finasteride reduces prostate cancer incidence but raises high-grade cancer risk, per Thompson et al. (2003) in 'The Influence of Finasteride on the Development of Prostate Cancer'. Tadalafil monotherapy improves lower urinary tract symptoms from benign prostatic hyperplasia, based on a meta-analysis by Dong et al. (2013) showing efficacy and safety.
Reading Guide
Where to Start
'A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum' by Vermeulen et al. (1999) is the starting point for beginners, as it provides foundational methods for measuring free testosterone, central to understanding hormonal effects in men's health.
Key Papers Explained
Vermeulen et al. (1999) 'A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum' establishes measurement techniques, which Harman et al. (2001) 'Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men' applies to aging declines. Rosen et al. (1997) 'The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction' and Rosen et al. (1999) 'Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5)' link low testosterone to reproductive outcomes. Ryan et al. (2012) 'Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy' and Antonarakis et al. (2014) 'AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer' build on androgen pathways for therapy resistance.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues on testosterone's role in metabolic syndrome and cardiovascular risk, extending Harman et al. (2001) findings. Prostate cancer therapies like abiraterone face resistance challenges identified by Antonarakis et al. (2014). No recent preprints available.
Papers at a Glance
Frequently Asked Questions
What methods estimate free testosterone in serum?
Vermeulen et al. (1999) in 'A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum' evaluated methods like equilibrium dialysis, finding apparent free testosterone concentration reflects clinical situations more accurately than total levels. These indexes account for nonspecifically bound hormone fractions. The study emphasizes reliable free testosterone measurement for androgen deficiency assessment.
How do testosterone levels change with aging in men?
Harman et al. (2001) in 'Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men' showed cross-sectional and longitudinal declines in total and free testosterone with age. Declines occur independently of chronic illness or medications in healthy men. This establishes aging as a direct factor in testosterone reduction.
What is the IIEF used for in reproductive studies?
Rosen et al. (1997) developed the International Index of Erectile Function (IIEF) in 'The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction' as a tool for evaluating erectile dysfunction. An abridged 5-item version (IIEF-5) serves as a diagnostic tool, per Rosen et al. (1999). Both scales enable standardized assessment in clinical research.
How does abiraterone affect metastatic prostate cancer?
Ryan et al. (2012) in 'Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy' found abiraterone improved radiographic progression-free survival and delayed chemotherapy in castration-resistant cases. It showed a trend toward better overall survival. Detection of AR-V7 predicts resistance, as per Antonarakis et al. (2014).
What are the effects of finasteride on prostate cancer risk?
Thompson et al. (2003) in 'The Influence of Finasteride on the Development of Prostate Cancer' reported finasteride prevents or delays prostate cancer appearance. Benefits include reduced urinary problems, balanced against sexual side effects and increased high-grade cancer risk. This informs risk-benefit discussions in prevention.
What role does testosterone play in cardiovascular health?
Shepherd et al. (1995) in 'Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia' showed pravastatin reduced myocardial infarction and cardiovascular death in men with hypercholesterolemia. The study links lipid management to heart disease prevention in contexts overlapping testosterone-related metabolic risks. No direct adverse noncardiovascular effects were observed.
Open Research Questions
- ? How accurately do current methods predict free testosterone levels across diverse populations beyond the evaluations in Vermeulen et al. (1999)?
- ? What factors beyond aging contribute to longitudinal testosterone declines in men, separating aging per se from comorbidities as in Harman et al. (2001)?
- ? Can AR-V7 detection reliably guide treatment resistance predictions for enzalutamide and abiraterone in larger cohorts, per Antonarakis et al. (2014)?
- ? What mechanisms underlie finasteride's dual effect of reducing overall prostate cancer incidence while increasing high-grade tumors, as in Thompson et al. (2003)?
- ? How do testosterone therapies interact with cardiovascular risks in aging men with metabolic syndrome?
Recent Trends
The field maintains 88,650 works with no specified 5-year growth rate.
High-citation papers from 1985-2014, such as Reul and de Kloet on corticosterone receptors (2552 citations), indicate sustained interest in hormone receptors.
1985No recent preprints or news in the last 12 months signal stable rather than rapidly expanding activity.
Research Hormonal and reproductive studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hormonal and reproductive studies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers